Antimicrobial-resistant Neisseria gonorrhoeae (NG) is a global public health issue that threatens effectiveness of current treatments of NG. Increased use of nucleic acid amplification tests (NAATs) in lieu of cultures makes obtaining clinical isolates for susceptibility testing difficult and samples collected in commercial transport buffer for NAATs do not preserve viable organism, while molecular methods of assessing antibiotic susceptibility do not require viable organism. We evaluated 243 NG-positive samples in Aptima transport media including urine, oral, and rectal swabs from Nigerian men who have sex with men for markers to penicillinase-producing NG, ciprofloxacin (GyrA and ParC mutations), and extended spectrum cephalosporins (ESCs, PenA mosaic [allele X], PonA, mtrR, PorB mutations) by real-time PCR. NG DNA was recovered in 75% (183/243) of samples. Of these, 93% (171/183) were positive for at least one resistance marker. We observed a prevalence of dual resistance markers to penicillin and ciprofloxacin at 46.2% (79/171). Six percent of samples (10/171) tested positive for the PenA mosaic (allele X) ESC marker. These data indicate that antibiotic-resistant NG is common in Nigeria. Laboratory and clinical capacity building in Nigeria should include development of methods to culture NG and determine antimicrobial susceptibility.
Costa LourençoAPRDBarros Dos SantosKTMoreiraBMet al. Antimicrobial resistance in Neisseria gonorrhoeae: history, molecular mechanisms and epidemiological aspects of an emerging global threat. Braz J Microbiol 2017; 48: 617–628.
3.
NewmanLRowleyJVander HoornSet al.
Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One2015;
12: e0143304.
4.
World Health Organization (WHO) guidelines for the treatment of Neisseria gonorrhoeae. Geneva: World Health Organization, 2016.
5.
UnemoM.Current and future antimicrobial treatment of gonorrhea – the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis2015;
15: 364.
6.
UnemoMShaferWM.Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future. Ann N Y Acad Sci2011;
1230: E19–E28.
7.
WiTLahraMMNdowaFet al.
Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action. PLoS Med2017;
14: e1002344.
8.
KatzARKomeyaAYKirkcaldyRDet al.
Cluster of Neisseria gonorrhoeae isolates with high-level azithromycin resistance and decreased ceftriaxone susceptibility, Hawaii, 2016. Clin Infect Dis2017;
65: 918–923.
9.
HookEW3rd.
Continued evolution of gonococcal antimicrobial resistance. Clin Infect Dis2017;
65: 924–926.
10.
World Health Organization (WHO), Department of Reproductive Health and Research. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae.
Geneva:
WHO, p.136, http://www.who.int/reproductivehealth/publications/rtis/9789241503501 (2012, accessed 13 September 2017).
11.
BuonoSAWatsonTDBorensteinLAet al.
Stemming the tide of drug-resistant Neisseria gonorrhoeae: the need for an individualized approach to treatment. J Antimicrob Chemother2015;
70: 374–381.
12.
KirkcaldyRDZaidiAHookEWet al.
Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005–2010. Ann Intern Med2013;
158: 321–328.
13.
BebellLMMuiruAN.Antibiotic use and emerging resistance: how can resource-limited countries turn the tide?Glob Heart2014;
9: 347–358.
14.
LatifASGwanzuraLMachihaAet al. Antimicrobial susceptibility in Neisseria gonorrhoeae isolates from five sentinel surveillance sites in Zimbabwe, 2015–2016. Sex Transm Infect 2018; 94: 62–66.
15.
TakuvaSMugurungiOMutsvangwaJet al.
Etiology and antimicrobial susceptibility of pathogens responsible for urethral discharge among men in Harare, Zimbabwe. Sex Transm Dis2014;
41: 713–717.
16.
NdowaFJFrancisJMMachihaAet al.
Gonococcal antimicrobial resistance: perspectives from the African region. Sex Transm Infect2013;
89: iv11–iv15.
17.
WindCMde VriesHJvan DamAP.Determination of in vitro synergy for dual antimicrobial therapy against resistant Neisseria gonorrhoeae using Etest and agar dilution. Int J Antimicrob Agents2015;
45: 305–308.
18.
GilesJHardickJYuengerJet al.
Use of applied biosystems 7900HT sequence detection system and Taqman assay for detection of quinolone-resistant Neisseria gonorrhoeae. J Clin Microbiol2004;
42: 3281–3283.
19.
GoireNFreemanKTapsallJWet al.
Enhancing gonococcal antimicrobial resistance surveillance: a real-time PCR assay for detection of penicillinase-producing Neisseria gonorrhoeae by use of noncultured clinical samples. J Clin Microbiol2011;
49: 513–518.
DonàVLowNGolparianDet al.
Recent advances in the development and use of molecular tests to predict antimicrobial resistance in Neisseria gonorrhoeae. Expert Rev Mol Diagn2017;
17: 845–859.
22.
OchiaiSIshikoHYasudaMet al.
Rapid detection of the mosaic structure of the Neisseria gonorrhoeae penA Gene, which is associated with decreased susceptibilities to oral cephalosporins. J Clin Microbiol2008;
46: 1804–1810.
23.
PetersonSWMartinIDemczukWet al.
Molecular assay for detection of genetic determinants associated with decreased susceptibility to cephalosporins in Neisseria gonorrhoeae. J Clin Microbiol2015;
53: 2042–2048.
24.
GoireNLahraMMChenMet al.
Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance. Nat Rev Microbiol2014;
12: 223–229.
25.
SpeersDJFiskREGoireNet al.
Non-culture Neisseria gonorrhoeae molecular penicillinase production surveillance demonstrates the long-term success of empirical dual therapy and informs gonorrhoea management guidelines in a highly endemic setting. J Antimicrob Chemother2014;
69: 1243–1247.
26.
PondMJHallCLMiariVFet al.
Accurate detection of Neisseria gonorrhoeae ciprofloxacin susceptibility directly from genital and extragenital clinical samples: towards genotype-guided antimicrobial therapy. J Antimicrob Chemother2016;
71: 897–902.
27.
TurnerKMChristensenHAdamsEJet al.
Analysis of the potential for point-of-care test to enable individualized treatment of infections caused by antimicrobial-resistant and susceptible strains of Neisseria gonorrhoeae: a modelling study. BMJ Open2017;
14: e015447.
28.
KeshinroBCrowellTANowakRGet al.
High prevalence of HIV, chlamydia and gonorrhoea among men who have sex with men and transgender women attending trusted community centres in Abuja and Lagos, Nigeria. J Int AIDS Soc2016;
19: 21270.
29.
WhileyDMSlootsTP.
Comparison of three in-house multiplex PCR assays for the detection of Neisseria gonorrhoeae and Chlamydia trachomatis using real-time and conventional detection methodologies. Pathology2005;
37: 364–370.
30.
CharuratMEEmmanuelBAkoloCet al.
Uptake of treatment as prevention for HIV and continuum of care among HIV-positive men who have sex with men in Nigeria. J Acquir Immune Defic Syndr2015;
68: S114–S123.
31.
AliSSewunetTSahlemariamZet al.
Neisseria gonorrhoeae among suspects of sexually transmitted infection in Gambella hospital, Ethiopia: risk factors and drug resistance. BMC Res Notes2016; 13: 439.
32.
VandepitteJHughesPMatovuet al.
High prevalence of ciprofloxacin-resistant gonorrhea among female sex workers in Kampala, Uganda (2008–2009). Sex Transm Dis2014;
41: 233–237.
33.
DuplessisCPuplampuNNyarkoEet al.
Gonorrhea surveillance in Ghana, Africa. Mil Med2015;
180: 17–22.
34.
Lagace-WiensPRDuncanSKimaniJet al.
Emergence of fluoroquinolone resistance in Neisseria gonorrhoeae isolates from four clinics in three regions of Kenya. Sex Transm Dis2012;
39: 332–334.
35.
BanwatEBAuduESEgahDZ.Antimicrobial susceptibility pattern of Neisseria gonorrhoeae isolated at the Jos University Teaching Hospital, Jos, Central Nigeria. Niger J Med2001;
10: 72–74.
36.
LewisDASriruttanCCoetzeeJ.Detection of multidrug-resistant gonorrhea in the Gauteng province. South Afr J Epidemiol Infect2012;
27: 199–200.
37.
EyreDWDe SilvaDColeKet al.
WGS to predict antibiotic MICs for Neisseria gonorrhoeae. J Antimicrob Chemother2017;
72: 1937–1947.
